本文へ移動
cccskills
無料GitHub で公開

es-cushing-shared-decision-making-second-line-therapies

This skill provides a shared decision-making framework for selecting second-line therapies in patients with ACTH-dependent Cushing's syndrome who have persistent hypercortisolism after transsphenoidal surgery or for whom surgery is not feasible. Clinical triggers include "failed TSS", "non-curative pituitary surgery", "persistent UFC elevation post-op", and "surgery contraindicated".

インストール方法を見る

含まれるファイル(1)

  • SKILL.md3.2 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Shared Decision-Making Approach for Second-Line Therapies in ACTH-Dependent Cushing's Syndrome

STEP 1 — Gather Information

Collect postoperative UFC or late-night salivary cortisol, pituitary MRI to assess residual/visible lesion, comorbidities (diabetes, hypertension, hepatic function, osteoporosis), prior treatments, patient values and preferences, and contraindications to specific therapies (e.g., liver disease for ketoconazole, pregnancy for mifepristone).
Action: Proceed to assess eligibility for each second-line option.

STEP 2 — Rule In / Rule Out

Determine if a resectable pituitary lesion is visible on postoperative MRI.

  • If lesion visible → consider repeat transsphenoidal surgery (TSS).
  • If no visible lesion → rule out repeat TSS and evaluate medical therapy, radiation, or bilateral adrenalectomy.
    Decision: If lesion visible, advance to repeat TSS evaluation; if not, move to medical therapy/radiation/adrenalectomy evaluation.

STEP 3 — Classify or Stratify

Stratify by clinical urgency and patient factors:

  • Life-threatening hypercortisolism (e.g., severe infection, psychosis) → prioritize bilateral adrenalectomy or rapid-acting medical therapy (etomidate, mifepristone).
  • Non-urgent: classify by patient preference for invasiveness vs medical therapy and comorbidities (e.g., avoid ketoconazole if hepatic impairment; consider mifepristone if diabetes/glucose intolerance).
    Action: Assign patient to a preferred modality category: surgical (repeat TSS or adrenalectomy), radiation, or medical therapy.

STEP 4 — Decide

Based on classification, discuss risks/benefits of specific options within the chosen category with the patient, then initiate shared decision-making to select therapy. Order required pretreatment evaluations (e.g., liver function tests for ketoconazole, pituitary MRI for radiation planning).
Action: Implement chosen second-line therapy and schedule follow-up cortisol assessment at 6–12 weeks.

Clinical Guardrails / Mimics / Pitfalls

Do not initiate radiation without first confirming medical control of cortisol; avoid bilateral adrenalectomy without discussing lifelong glucocorticoid dependence; do not use ketoconazole in significant hepatic impairment; avoid mifepristone in pregnancy; do not delay treatment in life-threatening hypercortisolism; monitor for Nelson syndrome after adrenalectomy; assess for hypopituitarism after radiation.

Concrete Clinical Example

A 45‑year‑old woman with persistent UFC 3× normal after TSS shows a 6 mm residual adenoma on MRI, normal liver function, and wishes to avoid lifelong steroids. After discussing options, repeat TSS is selected.

Source: Treatment of Cushing’s Syndrome: An Endocrine Society, 2015, DOI:10.1210/jc.2015-1818

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する